OncoMatch/Clinical Trials/NCT04831437
Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer
Is NCT04831437 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for cervix uteri cancer.
Uterine cervix cancer can be treated definitively with concurrent chemoradiation (external beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment duration can be shortened by increasing the dose per fraction of treatment which can reduce costs and patient exposure. The aim of our study is to determine the non-inferiority of hypofractionated radiotherapy compared with conventional treatment.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage IB, IIA, IIB, IIIA, IIIB, IIIC1
Excluded: Stage IA, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: pelvic radiotherapy
previous pelvic radiotherapy
Cannot have received: surgery
History of previous hysterectomy
Lab requirements
Kidney function
Creatinine clearance must be at least 30ml/min
Creatinine clearance less than 30ml/min [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04831437 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pelvic radiotherapy, surgery disqualifies patients from enrollment.
What disease stage is eligible?
Stage IB or IIA or IIB or IIIA or IIIB or IIIC1 is required.
Is there an age limit?
Yes. Patients must be 85 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify